[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the tease and the details (and the stock) are still the same. The latest pitch is based partly on upcoming catalysts, particularly the “winding down” of Phase 2 studies on their lead drug and the likelihood that they will soon get approval to start Phase 3 studies for this drug that has an FDA “orphan” designation, which they think will rocket the stock higher.
What follows has not been updated, edited or revised, but ALNY is now a $11 billion company with a share price of roughly $110, it has had its ups and downs after being teased two years ago, but it has been generally very strong and we last re-published this piece about a year ago when the stock was at less than half this price. I don’t know a lot about the company or the science behind it, and didn’t know much about it then either (sometimes I’ve got an opinion, sometimes I can just get you the stock name and ticker and let you get started on your own), so I’m republishing this instead of re-writing it — that will let us stay connected to the original stream of comments. If you want to see some of the more recent chatter on this, you can also check the article we wrote when Michael Robinson was using a similar “How to Live Forever” shtick in teasing this same company, about a month ago, for his Nova-X Report.
I hope you find the following helpful, but it at least answers the question so many have asked: “what’s Oxford Club’s ‘Magic Keys to Immortality’ stock?”]
—-following was published June 29, 2013 and has not been edited or updated—
“Just one company stands to make the lion’s share from this radical life extension phenomenon…
“It’s locked down nearly every patent behind this technology.
“The founder of this company, a Nobel Prize-winning scientist, is the same man who founded one of the most storied biotech companies ever.
“His first biotech outfit saw its stock go from $3.08 a share to over $240 a share. That’s when his company developed and released a treatment for a debilitating – and often deadly disease.”
I can see why so many folks have been asking about this latest pitch from the Oxford Club — not only do you get that kind of exciting story, but you also get the coincidence that the folks who buy investment newsletters tend to mostly be in their 60s and 70s and quite interested in health and rejuvenation and life extension, and the ad came in under the headline that …
“The First Person to Live to Age 1,000 Has Already Been Born…“
Presumably that’s going to be one of the people who are a few months old now, and you also have to see a real exponential hockey-stick chart of life expectancy to get to 1,000 years old — along, of course, with a complete change to the structure of human life on earth — but the more realistic-sounding projections, based on some big breakthroughs like the one being teased here, are that it’s possible for adults alive now to reach 150 years of age, and that the longer you live the more science will catch up with you and push that envelope further. Of course, you won’t be able to retire at 65 if you’re looking at making those monthly condo payments for another 80 years after that, but presumably you’ll be so strong and vibrant that you’ll be working as a longshoreman for a little fun and pocket change in your spare time.
But anyway, this Oxford Club pitch is that there’s a spectacular biotech company that’s got RNA technology patents locked up, and visionary leadership, and they’re going to shoot to the moon over the next few years — starting soon as they release their next FDA trial results in the days and weeks to come, and accelerating by next year as Phase III trials and possible drug approvals get closer to reality.
And no, it’s not the same idea as the “God Switch” ads still being run by Patrick Cox and the Agora folks — that’s a different “become immortal” strategy based on stem cells and they were (and are, and have been for a while) teasing BioTime (BTX). This is a different approach to living “forever.”
Here’s some more from the ad, talking about the huge success this scientist had with his last company:
“In the next 90 days, we’re expecting an unprecedented and shocking announcement from this gentleman’s new ‘start-up’ biotech company…
“It’s a ‘coming out party’ of sorts for this technology.
“And when this news hits the mainstream media, I believe it could become the most talked about technology breakthrough of our lifetimes. And the stock is likely to storm up the charts as a result.”
Here’s how they describe the actual science … and let me just warn you, from here on out I’ll be playing the role of “dumb guy”, the science is out of my sphere of understanding:
“Think of your cells like tiny photocopiers. Even if you have the highest-quality printer in the world, there will be a problem if you make copies of copies of a photograph. The little imperfections add up. Eventually you won’t even recognize the image.
“But, consider if you just used the original every time you wanted a copy. Then you could make perfect replicas for years and years.
“That’s what this company’s technology does.
“Its scientists have found a way to get the ‘original’ make-up of a cell. Its treatments convince the body to use the originals only, and to destroy any damaged ‘replacement’ copies.
Are you getting our free Daily Update
"reveal" emails? If not,
just click here...“The industry term for this medicine is ‘RNA Interference.’
“Biologically it works like this…
“RNA is a messenger, copying genes from an old cell to a new cell. But what happens when RNA starts transmitting imperfections to the new cells? The answer is what we call aging… when these imperfections add up, and our body starts breaking down.
“But ‘RNA Interference’ stops the RNA from passing along these imperfections. It interferes with these mistakes, so your genes only pass along the blueprint of the original ‘perfect’ cell.
“In other words: All your new replacement cells can be as perfect as the original cells….
“Right now, doctors treat you by working outside in – using either invasive drugs or surgery.
“But using RNA Interference, it’s possible to treat disease by going inside out. That’s because this technology makes it possible to ‘turn off’ harmful genes.
“For example, let’s say one tiny cell in your body begins producing cancerous cells. With RNA interference, doctors can keep the cancer cell from ever reproducing.
“In other words, you can destroy the cancer inside your cells, before it starts.”
And here’s the understatement of the day:
“It’s unlikely you’ll be able to get a shot or pill in the next five to 10 years to get you to age 1,000.”
But they turn that into “still damn good” in the following sentences:
“After all, RNA Interference is still a very new technology…
“At its current level of development, we are perhaps decades away from using it to live a thousand years.
“That said, I am certain this company’s technology will be used to add as many as 60 to 70 additional healthy years to your life.”
Not bad, eh? So which company is this? Clues, please:
“… a small, American-based company, near the campus of MIT.
“This unknown company has unlocked the secrets of RNA. At this very moment, it’s administering these treatments to hundreds of Americans… But those numbers could be on the verge of a dramatic rise. And here’s why…
“We are only months away from an explosive announcement from this biotech company… One that could show up on the front page of every financial newspaper and website across the country.
“This is the start of something bigger than the introduction of flight by the Wright brothers. Even bigger than the birth of personal computers in the 1970s….
“The company I’ve been telling you about was founded by a scientist we’ll call ‘Dr. Allen.’ Dr. Allen is one of our greatest living scientists. In the 90s, he won the Nobel Prize for a different biotechnology, something called gene splicing.
“He’s also a professor at MIT and a member of the prestigious Royal Society of London, which once included Sir Isaac Newton among its members.
“But beyond his many scientific credentials, Dr. Allen is also an incredible businessman. In the late 70s, he founded a company we’ll call ‘Bio-Inc.’
“It was a tiny start-up at the time, but today that company has over $2 billion in annual revenue.
“You’ll be interested to know that Bio-Inc’s stock is up more than 7,547% since Dr. Allen founded it.”
Sounds intriguing, no? Any more little details that we can feed into the Thinkolator? Perhaps just a few …
“… only a $1.3 billion market cap …
“It owns nearly all the patents related to RNA Interference… over 700 granted patents worldwide for RNA Interference. In total, it has over 300 granted or issued patents in the world’s major pharmaceutical markets – the United States, E.U., Japan… No other company comes this close to completely controlling this technology….
…it’s arranging 30 licensing deals with pharmaceutical and biotech companies right now. And even more deals are expected soon….
“Dr. Allen’s latest company has an advisory board made up of scientists from Harvard Medical School, MIT, Howard Hughes Medical Institute, Swiss Federal Institute of Technology and Koch Institute for Integrative Cancer Research. In just three months, this company will announce incredible medical results, which could shoot its stock to the moon.”
OK … so that’s the pitch on the company — how are they going to make us rich? We’re told that there’s a catalyst coming soon — results from one of their trials:
“Dr. Allen’s company is on the verge of announcing incredible results from a Food and Drug Administration study about its top RNA Interference medicine.
“This study, conducted with the Boston University School of Medicine, will be shocking even to most doctors.
“We know. We’ve seen the earlier FDA reports for ourselves.
“The results of this announcement should lead to immediate Phase 3 approval from the Food and Drug Administration. Meaning…
“The first RNA Interference treatment of its kind will soon be commercially available in the U.S.”
“… laser-focused on a treatment for a rare ‘orphan’ disease. By taking this unusual route to get this medicine on the market, the company cut down the final approval time for its RNA medicine to as fast as 12 months.
“Specifically, Dr. Allen’s team is going after a terrible, genetic disease that more than 40,000 people are diagnosed with each year. Most die from it within three years.
“At this point, Dr. Allen’s company is winding down its Phase 2 trials treating this ‘orphan’ disease… based on early reports we’ve seen, after a single dose of this RNA medicine, patients had a 94% reduction of the protein causing this genetic disease. In other words, most of the problems were “turned off” after a single treatment. In addition, side effects were non-existent… we fully expect this treatment will almost certainly pass into final Phase 3 testing in the next three months. And when the company announces this next stage of approval, this event alone could be worth millions in profits.
“The door will be wide open for brand new medicines developed by Dr. Allen and his scientists. In fact, they’re working on five new treatments as we speak….”
So who is being teased by the Oxford Club folks here? Thinkolator sez it’s Alnylam Pharmaceuticals (ALNY), which was actually one of the top teaser touts of 2012 after the folks at Casey Extraordinary Technology teased it back in May of last year at about $10 a share (it went to $18 or so at the end of the year, and recent strength has driven it to $30).
I think you probably all know well that I’m no doctor, and no scientific expert, but Alnylam Pharmaceuticals is a very active developer of early stage drugs that use RNA interference or RNAi technology — they’re not the only ones, there are other competing platforms and strategies that also aim to lasso the “turn off a gene” power of tinkering with RNA, including the one that’s probably a bit more well-known, Isis Pharmaceuticals (ISIS). And yes, ALNY is headquartered in Cambridge, not far from MIT, and the big brain on the board is Nobel-winning RNA-splicer (and MIT faculty member) Dr. Phillip A. Sharp — the A is for Allen, in case you’re wondering where the “Dr. Allen” bit came from.
They are also expecting Phase II data from their lead trial sometime this Summer, that’s the trial for their “orphan drug” to treat TTR Amyloidosis (the drug is called ALN-TTR02 at this point), and they do see this moving into a Phase III pivotal trial by the end of the year (assuming, of course, that good results continue). This is an exceedingly rare and terrible disease with no effective therapies, so the treatment would have to be pretty bad to not at least get the drug a fighting chance. You can see the rest of the pipeline here, the goal of the company is to advance at least five compounds into advanced stage clinical trials by 2015 (they call it their “5 in 15” campaign), which would presumably help to validate their RNAi platform and patents and technology and get other partners on board to work on other diseases.
The company has had a pretty steady drumbeat of positive-sounding announcements during the first half of this year, which has helped to spur the shares higher, and the last note I saw in their quarterly annoucements said they expect their Phase II TTR02 results by the end of June, so that’s awfully dang close to now … along with a “data rich” period of expected information being released about their preclinical and less-advanced products over the next few months. They’ve also been making the rounds of investment conferences recently, so you can check out some of those presentations here if you’re interested in hearing their pitch more directly, or the latest earnings call transcript here. That said, they’ve had plenty of periods of weaker news as well — they had a different Phase II trial fail a bit over a year ago, so these are not guaranteed compounds.
Financially, ALNY’s stock price can really only be justified because it’s a biotech stock that investors believe is creating a platform that will lead to a series of novel drugs inching closer to the market over the next several years. Their revenue is minuscule for a company that has a market cap now of almost $2 billion, and they have a couple hundred million in cash on hand but that’s only because they issued new stock this year to raise cash — they will be using all of that cash and more as their clinical development programs move forward, trials are expensive and they get more expensive as you move along to later stages (though their lead candidate, with a very small number of afflicted patients and orphan status to speed things up, may not cost as much to usher through the process as the average drug). The stock trades on sentiment about their clinical trials, and about speculation about what a real platform for RNAi drugs might mean — which almost means the share price is irrelevant, you can argue that the company is worth $500 million or $1 billion or $5 billion or whatever number in between, but it’s all based on the current drugs, all in early stages except for their lead orphan drug, continuing to show the promise of RNA. Massive returns from here, as have been achieved by a few biotechs that made the leap to becoming real “big pharma” names with real products and profits, are possible, I suppose, but that depends on the science working. And probably on a bit of luck, as well.
Oh, and yes, “Dr. Allen” was involved with one of those previous mega-successes — the stock they tease as “Bio-Inc” is Biogen-Idec (BIIB), and Dr. Sharp was the founder of Biogen. If performance like Biogen’s is the goal — and that would be a lofty goal, indeed — then it’s worth noting that even this clearly spectacular company has had some very weak periods of stock performance, so investors would have had to show either great prescience or great patience to enjoy all of that run. BIIB has been a huge success since 2000, running from $50 to almost $250 in just a couple years, and it was also hugely successful in the 1990s, running from a couple dollars in 1990 to almost $50 in 2000 … but it also had a “lost decade” there in the middle, bouncing from $35 to $70 and back again several times in the 2000s as their lead drugs showed promise and disappointment along the way.
ALNY last had a heyday for investors in the mid-2000s when their first compound were being readied for the clinic, and RNAi and SiRNA and other technologies and techniques to silence genes were just getting investors excited for really the first time. RNAi and the like have been very promising but very challenging develop for at least a decade now — that oft-cited quote that was in the ad that this is “The Greatest Medical Advance Since the Discovery of Antibiotics,” from an article in New Scientist, was published in 2005, when the first clinical trials for RNAi drugs seemed likely … it always takes longer than you think, and the FDA is always extra-worried about brand new treatments or technologies.
From what I can tell in the dumbed-down articles I’ve skimmed, the biggest issue with RNAi is how to delivery it to the right cells, a challenge that is being addressed in many different ways (intravenous, subcutaneous, oral compounds with engineered coatings, etc.).
Anything else I say about the technology or the company’s drugs in development will only further illustrate my ignorance … so I can tell you that the Oxford folks are almost certainly teasing Alnylam, but I don’t know what the news will be from their Phase II trial in the weeks (or days) ahead, how the other compounds in their “five in 15” campaign will develop, what partnered drugs might bring in milestones in the years to come, or how strong their patent portfolio is. This is a very young science still, at least when it comes to actually developing drugs, so I can easily see a successful drug approval in a couple years, if it does indeed come, being hugely important even if this first orphan drug won’t be itself a big enough seller to “make” the company.
If you’ve been an ALNY investor or follow the stock, or just paid more attention in science class than I did, feel free to jump in and let us know what you think of this one.
Hey Travis, what are the Motley Fools promoting with “project purple” and to get in before sept 7th?
Methusaleh (according to scripture) came close to living to 1000, but I doubt that we will even routinely reach Moses age of 120 by anyone born so far, even 150 would be a stretch. Maybe instead of relying on “science” interfering with nature based on mans wisdom, we should take biblical revelation and guidelines more seriously. Gen. 1:29 reveals the scientific FACT that fruits and vegetables take from the ground the elements from which man was originally formed and turns them into appealing foods, (taste, smell, texture of great variety) to provide the cells with the nutrients needed to sustain a long and healthy life. Instead of ENJOYING these blessings from the Creator man has focussed on PROFIT by fractionating these natural foods, denaturing them, destroying their nutritional value with heat and processing and substituting artificial and synthetic chemical compounds as a cheap substitute. If people ate natural foods grown in rich organic soil instead of the processed and preserved chemically grown crops in sterile soil with artificial fertilizers and poisonous pesticides we would see such a drop in what as rightly called “lifestyle diseases” we could probably close 75% or more of our hospitals.
I don’t want to live longer that what is planned for me. How about these famous scientists
finding a cure for aids, cancer, alzhelmer, or even the common cold. i’d jump on those stock in a heartbeat. In fact, I have some of those stocks. Tests take a long time for the FDA to approve new medication. But I am sure it will happen some day but unfortunately,
not in my lifetime. Enjoy your vacation, Travis.
I agree.
Not sure about the devine source of all this, but indeed the more processed the food, the more ill effects it seems to have. No company, nor the FDA (Michael Taylor’s second home, the first being Monsanto), will run serious, long-term studies on genetically modified foods—although results of those few studies that have been run break down according to funding source: those by industry find them safe; those without a financial interest find dangers.
“Methusaleh lived 1000 year…but who calls that liven’ when no gal will give in to no man
who’s 1000 years,” from It Ain’t Necessarily So, Porgy & Bess, Gershwins (who are both dead).
I’m enjoying all of the comments, but really, most of us don’t really care about the moral values. Question is the same one folks my age hear often, “Is it gonna go up? Is it gonna stay up?”
Depends on the Viagra shares !!!
LOL!!!!
If the the two “sure things” in life are “death and taxes”, and if now we can “live forever”, then that just leaves………
I have a degree in biotechnology and the science in the ad is just plan wrong. For instance it says “RNA is a messenger, copying genes from an old cell to a new cell”, there are two main types of RNA; messenger RNA (mRNA) and transfer RNA (tRNA) neither is responsible for copying genes from a new cell to an old one. mRNA copies gene information (transcription) to be transported to the ribosomes for translation into a polypeptide (protein). tRNA molecules match up with codon sequences on the mRNA and link amino acids together in a sequence that is dictated by the mRNA. They are both for protein expression. DNA polymerase is the molecule responsible for copying DNA.
Anyway don’t get sucked into this without understanding the science first. The company may have a technology that increases the longevity of cells or prevents errors from occurring but it sure as hell does not work as is explained in this ad. see this link for a video on RNA interference http://www.nature.com/nrg/multimedia/rnai/animation/index.html
Thanks; I squeaked out of SQNM before the collapse (see my earlier post), but as Mr. Buffett reminds us, investing in something that you do not understand can be dangerous, indeed. I may tiptoe a little past full understanding, but not very far.
Correction “Neither is responsible for copying genes from an old cell to a new one” I got old and new round the wrong way in that last post
Thank you Travis— You always come through! I had no idea they were running this promotion for so long. This is the first time I’ve seen it and I really appreciate your response.
Vince
An update on ALN-TTR02 (now called Patisiran) from Nov 10th: Phase II clinical trial results showed that multiple doses of patisiran led to robust and statistically significant knockdown of serum TTR protein levels of up to 96%. Knockdown of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, and durable, and similar activity was observed toward both wild-type and mutant protein. In addition, patisiran was found to be generally safe and well tolerated in this study (bit.ly/13N6W53). So, things are looking good from this perspective, and the share price has certainly gone up since this article was posted in June.
Just to be clear, RNAi technology can be used to fight genetic and infectious diseases so is not just about making people live longer but helping them have a better quality of life. Amyloid diseases as discussed here include Alzheimer disease, so even the 60 and 70-year old investors could see some benefits in the years to come.
Disease fighting would be important; Alzheimer’s is such a horror—any real advance would be so, so welcome!
Alzheimer’s is diabetes of the brain. Cut carbs, take a tablespoon of coconut oil a day and the symptoms go away. See Dr. Mary Newport ( neurosurgeon) on Youtube for how she “cured” her husband.
Am I looking at the wrong ticker? ALNY is over $80 a share?
thank you for this ‘head’s up’ about medium chain triglycerides and coconut oil! Amazing! She is actually a neonatologist, but is a pretty smart lady!
Much mahalo – I always get suckered in by those teasers. Will keep my eye on this one – watch the chart, possible winner, possible not. In any case, you saved me the price of a subscription that comes with VERY heavy affiliate marketing strategies.
With aloha,
Aunty
Suspect the “original” cell copies resides in the gametes and perseveres through the 20s – 30s in most specific tissues(stem cells) and/or beyond. Clue emanates from babies(complete youth) conceived from 30-40 year old females and a few beyond and men into very old age. That may derive from 99.5%(necessary for all organ/system/tissue transcription/function/positioning/integration precisely atomically/molecularly -something we take for granted as just occurring, “naturally” as it abounds about us not only in mammals but all the unbelievable life forms here on Earth)of DNA for humans being the same with the 0.5% data responsible for individual attributes(perception deceptive). Would indicate the genetic data for such youth/development is always available or at least the ability to reset the “domino cascade” present. Another clue among many involves 70-80 years olds regaining 15/20 vision after legally blind with appropriate cellular molecular/atomic optimum tissue specific cell needs are met on continuous basis.
Some of that genetic data has been replicated in dire circumstances for millions, maybe even 100’s of millions of years-what a copier!!!!!!!! That includes some from the very first cell and /or cell component successes!!!!!! This is no small feat even to initiate in CHON form or any other if even possible as by just looking around the neighboring planets(not even a hair, knat, dandelion, etc.) As for social enough galaxies in universe for every human on Earth to have their own(under population to the max-never ending natural resources/frontiers) Will need every human possible and eons more. 8.8 billion Earth like planets in the Milky Way alone!! That’s 1-2 billion more than existing population.
There are galaxies large enough to hold 1,000’s of Milky Ways!!
When you look at your symmetrical arms, legs, feet, hands, etc. or consider your organs(brain, heart, liver, eyes, ears, etc.) consider each and every cell that comprises them and the complete integrated/complimentary systems which are comprised of the trillions of cells necessary for each of us to function did not happen by chance or at random but were atomically numerically transcribed/structured/positioned with continued immense interaction. The brain formation and all the data for it alone is enormous with very special specific atomic/molecular needs and protections, Yet the eyes’ tissue specific molecular needs are quite different but with common matrix requirements. Natural as they do a very different function.
David; Are you making a case for DESIGN requiring a DESIGNER, i.e creation as opposed to evolution, or what was your point?
Why cant you have both?…something did the initial design and set fractal evolution in motion to see where it would go. Thousands of modern experiments follow this pattern exactly. Certainly Genesis and the Big Bang (good name for a rock group!), plus all that’s happened since is starting to look spookily similar (give or take a day or two in the authors diary notes)
Good possibility.
NO, your statement reflects YOUR state of mind more than anything.
The atomic complexity needed for life is certainly far greater than anything we have ever designed to this point and very probably far into the future and so far ours is the only certain intelligence observed. The planets around us exhibit little, if any, discovered present life or organic precursors other than Mars perhaps one cell artifacts. This is after 4,000,000,000-5,000,000,000 years. New evidence indicates Earth had ecosystems 3,500,000,000 at least. This seems significantly relevant to the difficulty in life development. But then many liquid atomic solutions are influenced impressively by adjacent substances esp. when combined with their properties. This appears quite conducive to development of films/membranes/barriers/skins, but quite a jump to necessary cell systems and replication.
Foods are quite deceptive. Even the “best” “organic” grown do not supply the tissue specific cell optimum needs. Some foods much better than others for particular tissues but still quite short in atomic/molecular needs. Chemistry is helping this in concentrating known specific needs, but delivery problems for whatever bio reason complicate too. Most obesity and its health results probably stems from those with taste bud affinity for fats and sweets(hydrocarbons with high energy) causing a greater ability to survive long durations without food. Even today those without such a taste bud affinity would probably starve without intervention. All for now. Aging not natural. Bodies made to go on indefinitely.
David; Would like to know your basis for your statement: “Even the “best” “organic” grown do not supply the tissue specific cell optimum needs.’ I will agree first and foremost that the word “organic” is much abused. Depending on the previous use of land the fact that no chemical fertilizers or pesticides are used CURRENTLY do not make produce “organic” by my definition. Conventional farming methods DESTROY the lands ability to RENEW itself, by that I mean that the microbial life of the soil and earthworms that naturally aerate the soil are gradually killed off, and the breakdown of rock that contains essential trace minerals also is greatly diminished. The essential organic matter that absorbs the rain for plant use and prevents run-off also diminishes with the application of commercial fertilizers containing sulfuric acid, resulting in a progressively sterile soil that like a junkie on drugs requires an ever increasing “injection” of NPK, the only, or at least primary elements that modern day agriculture concerns itself with. My point is that even though “trace minerals” are required only in minute quantities, they are ESSENTIAL and without them the body can not manufacture the complex proteins needed for very specialized applications.
By that standard your statement MAY be correct, in that it takes many years of organic husbandry to restore conventionally farmed land to full fertility. Green crops need to be plowed down, and natural trace mineral fertilizer applied before it can truly be called organic, the point being that plants can not take up from the soil what does not exist. Add to that the fact that plants have been bred that survive primarily on NPK applications and you have a situation of healthy appearing plants that are totally nutritionally inadequate.
Come come now boys…… did medieval man live to be 200 coz chemical fertilizers hadnt been invented to pollute the soil and earthworms abounded?……..or is that a load of manure? Methinks you’all worry too much. Live for the day coz one of them will be your last.
The point is very specific system/tissue specific MOLECULAR/ATOMIC cell requirements cannot be met by food without identification/ extraction/delivery, organic or not organic, virgin soil or not. The lack of toxins is better obviously but that is not the point either. Basis is developing research and some intuitive 34/36 ACT quantitative analysis scores.
Some superfoods come close to optimum cellular foods. Try spirulina and goji berries or here in the desert wolfberries, a native goji. I do perform better after eating them. Have taken spirulina hundreds of times before tennis, skiing and mountain biking. Helps a little.
Guess what? You cannot do a randomized double blind placebo controlled trial on yourself.
Congratulations on discovering the placebo effect.
“Superfood” sellers are just like vitamin mongers, herb sellers and Herbalife nutrition club members: they all know that if you can’t fool the average American consumer, who CAN you fool?
A great change, if these developments continue with more puzzle pieces being discovered with appropriate restitution, to consider would be the increased loss if death ensued from accident not timely addressed or some other crisis health condition i.e had extensive extended life. One should consider the value or place of telomere/telomerase codon/protein sheath chemical actuated genetic expression. Some compared to pages of book for or lack of various cell denigrations. Probably more like atomic/molecular facets with extensive significant and non-significant atomic/molecular variance. The bio cell data is monstrous in complexity but with continuing revelation this will happen. The economics are the greatest encumbrance (cash flow) yet so much is squandered on things much less significant. Billions on improved instruments specifically dramatically enhanced resolution/identification/manipulation biochem(molecular/atomic) devices especially.
I somehow missed this discussion. I am skeptical of the company under discussion, but will review it further. Anylam has to be a huge “sell” at this point, as I question how it is being run.
Alnylam’s lead candidate is a transthyretin-silencing RNAi for a rare form of amyloidosis. They are pursuing this just to get orphan drug designation. This is a rare disease, folks. It is difficult for me to imagine them recouping development costs. Anylam has some clever ideas. These include RNAi directed against antithrombin III, the physiologic inhibitor of thrombin, factor IX and factor X, as a therapy for hemophilias A and B as well as rarer bleeding diatheses. They conjugate RNAi to N-acetylgalactosamine, which gets taken up by the hepatic asialoglycoprotein receptor into clathrin-coated pits. I have serious doubts about the long term efficacy of this approach. A preparation so administered it like to tweak Toll-like receptors and lead to endogenous interferon elaboration. The agent must be administered frequently, at high doses, and tachyphylaxis may set in. They have a clever program to knock out expression of ZZ-phenotype alpha1-proteinase inhibitor as a means of preventing cell accumulation that leads to cirrhosis, but there development for this is still preclinical, in mouse model. The idea that it will work for decades to prevent liver disease…..this is not proven yet.
The best approach is ddRNAi therapy, for which tiny Australian Benitec is in the dominant IP position. Benitec’s first patients with HCV will be dosed with its TT-034 agent encoding three sharp hairpain RNAi’s against well-conserved regions of the HCV genome. If it works, it will be a one-dose HCV cure. Arrowhead Research is developing an RNAi therapy for HBV using a lipid nanoparticle. Their approach will go into clinical trials in Hong Kong HBV patients in Q1.
Full disclosure. I am long Benitec (BNIKF) here. It is cheap, not being followed by any analyst, and poised to succeed and has good cash flow. Its first patients for TT-034 will be dosed any day now. If their agent works, expect the sheets to be shaken and people to pile into its shares. A lead investor in that company is Kevin Buchi, who ran Cephalon.
I agree with Dr. KSS on Benitec–big upside there. Interestingly, there is also an RNAi related article on SA today touting Tekmira (TKMR) saying “we think that Tekmira has a substantial lead in the RNAi field.” Benitec has the advantage of being much more undiscovered at this point and the science is excellent.
The living 1,000 years hype is just that. From an investment and medical standpoint, the RNAi field is quite exciting. Finding the correct company or companies to invest in is crucial however. I fear that this company is overhyped and there are much better choices–like Benitec.
I belong to Oxford Club, but I can’t seem to get them to send me the book : RNA Interference “Ticket to Centuries of Health and Wealth” by Dr. Allen. Can someone else get me that book? 701-441-9810
Single-Molecule Unfolding Force Distributions Reveal a Funnel-Shaped Energy Landscape
The protein folding process is described as diffusion on a high-dimensional energy landscape. Experimental data showing details of the underlying energy surface are essential to understanding folding. So far in single-molecule mechanical unfolding experiments a simplified model assuming a force-independent transition state has been used to extract such information. Here we show that this so-called Bell model, although fitting well to force velocity data, fails to reproduce full unfolding force distributions. We show that by applying Kramers diffusion model, we were able to reconstruct a detailed funnel-like curvature of the underlying energy landscape and establish full agreement with the data. We demonstrate that obtaining spatially resolved details of the unfolding energy landscape from mechanical single-molecule protein unfolding experiments requires models that go beyond the Bell model.
Lucy Christiana, Lady Duff Gordon (Mrs Morgan born on 13 June) (née Sutherland) Palm print of showed a protective square at the end of travel line a mark of protection from catastrophic drowning over lapping the water affined criticality from cancer whereas W.T.Stead was drowned being born in July 16. who had a cross at the end of travel line
Single-Molecule Unfolding Force Distributions Reveal a Funnel-Shaped Energy Landscape in Telomerase -reg
Single-Molecule Unfolding Force Distributions Reveal a Funnel-Shaped Energy Landscape in Telomerase Symmetry breaking dynamics
The protein folding process is described as diffusion on a high-dimensional energy landscape. Experimental data showing details of the underlying energy surface are essential to understanding folding. So far in single-molecule mechanical unfolding experiments a simplified model assuming a force-independent transition state has been used to extract such information. Here we show that this so-called Bell model, although fitting well to force velocity data, fails to reproduce full unfolding force distributions. We show that by applying Kramers diffusion model, we were able to reconstruct a detailed funnel-like curvature of the underlying energy landscape and establish full agreement with the data. We demonstrate that obtaining spatially resolved details of the unfolding energy landscape from mechanical single-molecule protein unfolding experiments requires models that go beyond the Bell model.
Funnelling protein folding related Telomerase symmetry breaking dynamics evolved:
Oxford astrogenetics dept with Sankaarbvelayudhan nandakumar as team member along with President of Royal astronomical society have found out some interesting solitonic vortices in Tolemerase may be responsible for symmetry breaking cross polarised dynamics.A new protein folding strain that can be evalauted at the strain cross over points that deal with sudden reversal dynamics at middle point Knee Frequency hopping in between the shortening and expanding Telomerase that act like aspring deals with protein processing .This failure related upward and downward force in fact initiate a shearing force at the breaking pointas skew matrics scattering.The protein folding process is described as diffusion on a high-dimensional energy landscape is understandable via cross polarised resonating dipolar magnetic field acting as an inductive that resonate for vortices Experimental data showing details of the underlying energy surface are essential to understanding Tolemerase folding leading to cancerous cells. So far in single-molecule mechanical unfolding experiments a simplified model assuming a force-independent transition state has been used to extract such information. Here we show that this so-called Bell model, although fitting well to force velocity data, fails to reproduce full unfolding force distributions. We show that by applying Kramers diffusion model, we were able to reconstruct a detailed funnel-like curvature of the underlying energy landscape and establish full agreement with the data. We demonstrate that obtaining spatially resolved details of the unfolding energy landscape from mechanical single-molecule protein unfolding experiments requires models that go beyond the Bell model.
This in a way decoded the graphical interpretation of dual frequency resonance involved by dipole resonance at the in middle frequency reversal and forward oscillations involved in quantum entanglement involved in pie dynamics , of Telomerase revealing the basic Astrogenetic theory involved. It is suspected that lunar waves simulate a cross polarised dynamics Telomerase dynamics that deal with cancerous growth.
The amplitude shaping involves a dual Gaussian amplitude grating creating antistoke wp and Stokes ws bands, while the pie phase shaping involves a narrow pie-phase gate located at the center of Telomerase band responsible for such symmetry breaking.
Coherent Raman scattering, in which molecular vibrations are driven coherently through stimulated excitation by laser beams, offers new possibilities for ultra sensitive detection due to the greatly amplified signal strength.[, which is the most popular technique among the coherent Raman scattering family, the beating between a pump (at wp) and a Stokes (atws) beam actively drives the molecular oscillators at the difference frequency wp_ ws. Under their joint action, a vibrational coherence, a coherent superposition between the ground state and the excited vibrational state, is created among different molecules throughout the sample. Through a further interaction with wp, this vibrational coherence can be converted pulse (e.g. 10 fs pulse duration) excites more non-resonant background than resonant signal, as the electronic resonance is largely detuned for much of the broadband wp and was components.
Second, phase shaping could allow the identification of narrowband Raman spectral signature in the fingerprint region through spectral interferometry. Without this, Raman spectral information would be masked by the broadband excitation required by the above bandwidth matching condition. Therefore, the combination of amplitude and phase shaping gives rise to both detection sensitivity and spectral specificity.
The opposing stoke and antistoke of lower frequency ,middle frequency, and higher frequency entanglement could be used to amplify the output energy in erratic cancerous cell growth in understanding the magnetic field vortices that glide over the middle squeezing point of Telomarase.This resonance act as converging and diverging nozzle dynamics towards a breaking point dipole .
An observation of cross at theend of palm print indiacte a real cross polarised middle frequency dynamics of Telomerase which call for an interesting water affined genetic constraints even though the meeting point of health line with life line indicate a catastrophic influence.
Sankara velayudhan Nandakumar,Oxford Astrogeneticist
Single-Molecule Unfolding Force Distributions Reveal a Funnel-Shaped Energy Landscape in Telomerase -reg [Incident: 101001-000006 “news@nature.com”
HUH????
DOUBLE HUH, or is that a ten bagger?
Translated into short-form it either means, “Trust me, I’m a doctor, and this stock is going up”, or it means, “Trust me, I’m a doctor, and this stock is going down.
Sounds way out there:-)
Do you suffer from schizophrenia?
Looks like a reprint of an article he was lucky enough to have published, despite the fact the entire first paragraph is repeated. As to what it has to do with RNAi, your guess is as good as mine.
I guess this is going to rock the biotech industry, and make investors turn their attention to biotech companies.
There are also companies in other countries doing trials & research on the same thing; I think they are also linked together, and sharing their findings and results to make the RNAi more pronounced and effective. A big turn in human life !
God bless and long live all human being
Many consider the RNAi field to be the Third Wave in the biotech industry–the next big thing. As I said previously, I think that there are much better choices of companies than the one being “hyped.”
ALNY is at $80 a share!!! NO way!